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Background
HD IL-2 was FDA approved for advanced mRCC, but the
data supporting its use dates to the 1990’s. We designed
the PROCLAIMSM registry, including retrospective and
prospective cohorts, to study modern outcomes and inter-
actions with prior or subsequent targeted therapies. We
now report survival analysis from the Registry and the
effect of prior TT therapy.
Methods
Inclusion criteria required patients receive at least one
dose of IL-2. Survival for both cohorts (N=408) is current
to March 16, 2015.
Results
The overall response rate (ORR) and mOS are described
in Table 1. In the retrospective cohort, the 1, 2, and 3 year
survival rates were 89%, 69%, and 61% respectively for
patients with stable disease (SD). Similarly, in the prospec-
tive cohort, 1 and 2 year survival rates for patients with
SD were 95% and 76%, respectively. The mOS was not
reached for patients with SD in both cohorts. There was a
significant difference in mOS between SD and PD patients
in the prospective cohorts, NR vs 13.9 months, p < 0.0001,
there was no significant difference in mOS between SD
and PD in the retrospective cohort. For patients in the ret-
rospective and prospective cohorts who had prior targeted
therapy (TT), the mOS was 15.3 and 22.1 months, respec-
tively. Patients who did not receive TT before HD IL-2
therapy, the mOS was 48.9 months and NR, in the retro-
spective and prospective cohorts, respectively. There were
4 treatment-related deaths in 408 patients.
Conclusions
PROCLAIM data demonstrate that SD, previously
grouped with the non-responders, has extended survival
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Table 1
Updated March 16, 2015 Retrsopective Cohort (2007-2012)N=97, 11 sites Prospective Cohort (2011-2015)N=311, 39 sites
mOS, months 48 NR
Median follow-up, months 43.8 18.7
1,2,3 year survival rate, CP/PR 100%, 89%, 84% 100%, 85%, 79%
1,2,3 year survival rate, SD 89%, 69%, 61% 95%, 76%, n/d
ORR 20% (CR: 5%, PR: 15%) 16% (CR: 3%, PR: 13%)
CR+PR+SD 49% 55%
mOS no prioir TT/prior TT 48.9 (n=82)/15.3 (n=15) NR (n=266)/22.1 (n=45)
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rates. TT prior to HD IL-2 therapy was associated with
a lower mOS. These data support that HD IL-2 has
favorable safety profile compared to data in the original
package insert and remains an effective first line therapy
for eligible patients with mRCC.
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